What was Sila Realty Trust—and what is its status now?
Sila Realty Trust, Inc. was an internally managed healthcare real estate investment trust focused on net-leased facilities across the continuum of care. Its portfolio included medical outpatient buildings, inpatient rehabilitation hospitals, surgical facilities, and specialty properties leased to healthcare operators. The company traded on the New York Stock Exchange under the ticker SILA after its June 2024 direct listing, but it is no longer a standalone public company.
Sila's final filings remain a useful case study in healthcare net-lease economics and transaction valuation. The merger-closing Form 8-K confirms that the former corporation ceased to exist and the surviving company became privately owned.
How did Sila Realty Trust make money?
Sila earned almost all revenue by owning healthcare properties and collecting contractual rent. Under many triple-net leases, tenants paid property taxes, insurance, maintenance, and other operating costs. This improved property-level predictability but concentrated risk in healthcare operators whose rent capacity depended on patient volumes, reimbursement, labor costs, and regulation.
How did rent become cash flow?
Which revenue streams mattered?
| Revenue stream | FY2025 amount | Economics | Key sensitivity |
|---|---|---|---|
| Rental revenue | $196.3M | Contractual rent from operating healthcare properties | Tenant credit, renewals, occupancy, escalators, and lease enforcement |
| Real estate note interest | $1.2M | Interest from financing arrangements tied to healthcare development | Borrower execution, collateral value, and repayment timing |
| Property dispositions | Not recurring revenue | Sales recycled capital and could create gains or impairment losses | Market liquidity, cap rates, and asset-specific conditions |
This was an asset-spread model: property yields and rent growth needed to exceed the cost of capital while preserving liquidity for dividends and acquisitions. The 2025 Form 10-K makes lease design, tenant quality, debt pricing, and acquisition discipline the core variables.
Which properties, tenants, and markets drove the portfolio?
At year-end 2025, Sila owned 140 healthcare properties and three land parcels: 124 single-tenant, 14 multi-tenant, and two vacant properties. By March 31, 2026, sales and one acquisition reduced the count to 137 while rentable area remained near 5.3 million square feet. High occupancy and long leases supported value, but specialization heightened operator and reimbursement risk.
How strong was occupancy and lease visibility?
Where was rent concentrated?
PAM Health was the only tenant representing at least 10% of annual rental revenue. Its 15 leases covered 708,817 square feet and generated $31.6 million, or 16.1% of FY2025 rental revenue, with expirations concentrated from November 2044 through December 2045. That long term improved visibility but made operator-level monitoring essential.
What did Sila Realty Trust's final reported quarter show?
The quarter ended March 31, 2026 was Sila's final full quarterly report before closing. Rent and Cash NOI grew mainly because of acquisitions; same-store performance was positive but modest, consistent with a long-lease portfolio whose organic growth comes chiefly from contractual escalators.
Which lines improved most?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Total revenue | $52.7M | $48.3M | Growth reflected added properties and contractual rent progression. |
| Net income | $12.4M | $7.9M | The 57.3% increase also benefited from lower impairment and a disposition gain. |
| Cash NOI | $46.3M | $41.2M | Non-same-store Cash NOI rose to $5.5M from $0.7M. |
| Same-store Cash NOI | $40.7M | $40.4M | Approximately 0.7% growth indicated stable but low organic expansion. |
| AFFO | $33.5M | $29.4M | AFFO removed several noncash and transaction-related items. |
| Quarterly dividend | $0.40/share | $0.40/share | The payout equaled 66.7% of Q1 2026 AFFO per share. |
Was operating momentum improving?
The official Q1 2026 results also disclosed a $43.3 million inpatient rehabilitation acquisition in Oklahoma City and four property sales totaling $25.1 million. This combination illustrates Sila's active portfolio management immediately before the transaction.
Why did the 2021 healthcare pivot matter?
Sila's final form followed several strategic changes. The 2021 data-center sale created a healthcare-focused REIT and sharply reduced leverage; internalization, rebranding, and the NYSE listing then established the structure that enabled a public-company sale process.
-
2013The Maryland corporation was formed. Its original externally advised structure shaped early capital raising and fee economics.
-
2019The merger with Carter Validus Mission Critical REIT added scale and a mixed healthcare/data-center portfolio through consideration valued at about $952.8 million.
-
2020Management was internalized and the company rebranded as Sila Realty Trust, eliminating the former external advisory arrangement and aligning operating control with the REIT.
-
2021Sila sold 29 data centers for $1.32 billion, repaid substantial debt, and paid a $1.75-per-share special distribution. The business became a pure healthcare real estate platform.
-
2024A one-for-four reverse split preceded the June 13 NYSE direct listing, giving existing holders liquidity and establishing a public trading reference.
-
2025Six healthcare acquisitions totaling $148.9 million accelerated portfolio growth while increasing debt and interest expense.
-
2026Sila agreed to a $2.4 billion transaction with Blue Owl affiliates and closed on July 1, ending the standalone public-company story.
What did the data-center sale change?
The 2021 portfolio-sale announcement reported about $1.29 billion of net proceeds, repayment of $450.8 million of notes and $403.0 million of credit-facility borrowings, and a $392.7 million special distribution. The clearer healthcare identity simplified valuation but increased operator, reimbursement, and reuse concentration.
What gave Sila a competitive advantage?
Sila's advantages were financial and operational rather than brand- or network-based: specialized underwriting, healthcare operator relationships, internal management, long leases, and access to unsecured credit. It also benefited from demand for outpatient, rehabilitation, and specialty care outside acute-care hospitals.
Where was the moat limited?
Real estate remains contestable. Public REITs and private capital with greater liquidity could accept lower yields, bid more aggressively, or grant larger tenant concessions. Specialized properties did not create patent-like protection.
The strongest strategic resource was therefore not any single building. It was the combination of underwriting capability, operator relationships, portfolio data, and financing access. Those resources were valuable but not impossible to replicate, which explains why scale and cost of capital remained central competitive constraints.
How financially strong was Sila before the sale?
Sila entered 2026 with adequate liquidity, mostly hedged debt, and a dividend covered by AFFO, although growth had lifted leverage and interest expense. At March 31, principal debt was $690.0 million, the weighted-average rate was 4.7%, net debt was 33.4% of enterprise value, and liquidity was $465.8 million.
What did FY2025 cash flow support?
| Financial item | FY2025 | Why it mattered |
|---|---|---|
| Total revenue | $197.5M | Up 5.7% from FY2024, with acquisitions expanding non-same-store rent. |
| Net income | $33.1M | A 16.8% net margin, but GAAP earnings included depreciation and impairment effects. |
| AFFO | $120.9M | AFFO of $2.18 per diluted share better approximated recurring distributable performance. |
| Operating cash flow | $119.1M | Covered $88.8M of cash distributions by about 1.34 times. |
| Property capital and other costs | $8.3M | Operating cash flow less these expenditures was approximately $110.9M. |
| Acquisition investment | $148.9M | Growth investment exceeded internally generated cash and was partly debt funded. |
| Interest expense | $32.8M | Up 54.5% from FY2024 as borrowings and rates increased. |
Was the dividend sustainable?
The payout left a buffer but could not fund the full acquisition program. Credit capacity, asset sales, and capital access remained necessary, making the spread between property yields and borrowing costs crucial.
Who owned and governed Sila before the merger?
Sila had one common-stock class and 55,241,098 shares outstanding during the merger proxy period. BlackRock exceeded 10%, while two separately disclosed Vanguard entities each exceeded 5%. Directors and executives collectively owned less than 1%, providing alignment without voting control.
| Holder or group | Shares disclosed | Ownership | Governance significance |
|---|---|---|---|
| BlackRock, Inc. | 5,582,302 | 10.11% | Largest disclosed beneficial holder; institutional voting mattered in the merger process. |
| Vanguard Capital Management | 2,860,115 | 5.18% | A second large passive or institutionally managed block. |
| Vanguard Portfolio Management | 2,797,133 | 5.06% | Separately disclosed ownership added to institutional influence. |
| Michael Seton, former CEO | 290,310 | Less than 1% | Management alignment without voting control. |
| Directors and executive officers as a group | 521,068 | 0.94% | Board and management could not determine the outcome independently. |
Why did transaction incentives matter?
The definitive merger proxy disclosed vesting and cash conversion of equity awards plus potential severance benefits. These interests were relevant to incentive analysis, alongside the proxy's account of board deliberations and adviser work.
What opportunities and risks shaped the standalone story?
Sila could grow by financing healthcare facilities, acquiring at attractive yields, diversifying tenants, extending leases, and recycling weaker assets. Higher interest rates could narrow acquisition spreads.
Which filing risks were most material?
| Risk | Financial transmission | Evidence to monitor |
|---|---|---|
| Tenant concentration and credit | Missed rent, restructuring, legal costs, or impairment | PAM Health exposure; 59.4% of rent from below-investment-grade or unrated tenants |
| Healthcare reimbursement and regulation | Lower operator margins weaken rent coverage and demand | Medicare and Medicaid policy, licensing, certificate-of-need rules, and labor regulation |
| Interest rates and refinancing | Higher expense, lower acquisition spreads, and pressure on property values | Weighted borrowing rate, hedge maturities, and credit-facility utilization |
| Specialized-asset re-leasing | Downtime, re-leasing costs, demolition, and lower proceeds | Vacant assets, impairment charges, operator bankruptcies, and disposition pricing |
| Acquisition competition | Lower cap rates and weaker returns on incremental capital | Transaction volume, private-capital bids, and management's target yields |
The Stoughton property showed that high occupancy is not equivalent to low risk: operator failure can leave a purpose-built facility requiring time and capital to re-lease. A 50-basis-point increase on year-end 2025 variable debt would have added about $0.8 million of annual interest expense.
Why did the Blue Owl transaction redefine valuation?
A continuing REIT would be valued from Cash NOI growth, AFFO, leverage, capitalization rates, and cost of capital. The Blue Owl transaction replaced those uncertain cash flows with $30.38 per share in a deal announced at about $2.4 billion. After closing, merger consideration—not an open-ended terminal estimate—defined value.
Which DCF drivers mattered before closing?
| Valuation driver | Standalone evidence | DCF implication |
|---|---|---|
| Organic NOI growth | Q1 2026 same-store Cash NOI grew about 0.7% | Low organic growth makes terminal assumptions and acquisition economics more important. |
| Acquisition growth | $148.9M invested in six operating properties during FY2025 | Forecast growth required capital deployment and financing, not only existing-portfolio escalators. |
| Cost of debt | 4.7% weighted-average rate at March 31, 2026 | Higher refinancing costs reduce free cash flow and can raise the discount rate. |
| Lease duration | 10.1-year weighted-average remaining term | Long contracts reduce near-term cash-flow volatility but can limit rapid rent repricing. |
| Terminal capitalization rate | Not a company-reported metric | A small cap-rate change can materially alter real estate terminal value. |
The transaction announcement and approval release document the completed cash exit. The deal also suggests that private capital can value long-duration healthcare assets differently when financing and management sit inside a larger platform.
What should students and analysts monitor in a comparable healthcare REIT?
Sila no longer reports standalone results, but its final disclosures provide a monitoring template for healthcare landlords. Useful metrics connect property performance to tenant health and capital structure; acquisitions can make headline growth look strong even when existing assets barely expand.
Which KPI relationships reveal quality?
| KPI relationship | Sila reference point | Interpretation |
|---|---|---|
| Same-store Cash NOI growth versus total Cash NOI growth | About 0.7% versus 12.3% in Q1 2026 | The gap showed that acquisitions, not organic rent growth, drove most expansion. |
| Dividend per share divided by AFFO per share | 66.7% in Q1 2026; about 73.4% for FY2025 | A lower payout provides a cushion for debt service and reinvestment. |
| Fixed debt divided by total debt | 76.1% at March 31, 2026 | A higher fixed share reduces immediate rate sensitivity but does not eliminate refinancing risk. |
| Rent from top tenant divided by rental revenue | 16.1% from PAM Health in FY2025 | Concentration can dominate portfolio risk even when properties are geographically dispersed. |
| Operating cash flow divided by cash distributions | Approximately 1.34x in FY2025 | Coverage above one indicates cash generation exceeded distributions before acquisition spending. |
Analysts should reconcile GAAP net income with FFO and AFFO rather than treat them as interchangeable. Real-estate depreciation differs from industrial depreciation, but capital expenditure, leasing costs, incentives, and credit losses still consume cash; both the reconciliation and cash-flow statement matter.
What is the key takeaway from Sila Realty Trust's company analysis?
Sila's final model was clear: long leases, high occupancy, and contractual escalators converted specialized healthcare real estate into recurring Cash NOI and AFFO. Its evolution from an externally advised mixed-asset REIT into an internal healthcare pure play made the portfolio easier to finance, value, and acquire.
As an MBA case, Sila illustrates the trade-off between focus and concentration. Selling data centers reduced leverage and clarified strategy, but increased exposure to reimbursement, operator credit, and specialized-asset risk. Same-store Cash NOI, payout, hedging, tenant concentration, and acquisition spreads explain more than revenue alone.
Sila Realty Trust is no longer a public company. Researchers should use its last full-year results, final quarterly report, merger proxy, and closing filing as a closed historical record of how a healthcare REIT built, financed, and monetized a long-duration property portfolio.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.
